|
1
|
Kreth FW, Thon N, Simon M, Westphal M,
Schackert G, Nikkhah G, Hentschel B, Reifenberger G, Pietsch T,
Weller M, et al: Gross total but not incomplete resection of
glioblastoma prolongs survival in the era of radiochemotherapy. Ann
Oncol. 24:3117–3123. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sanai N, Polley MY, McDermott MW, Parsa AT
and Berger MS: An extent of resection threshold for newly diagnosed
glioblastoma. J Neurosurg. 115:3–8. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lacroix M, Abi-Said D, Fourney DR,
Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch
SJ, Holland E, et al: A multivariate analysis of 416 patients with
glioblastoma multiforme: Prognosis, extent of resection, and
survival. J Neurosurg. 95:190–198. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tsitlakidis A, Foroglou N, Venetis CA,
Patsalas I, Hatzisotiriou A and Selviaridis P: Biopsy versus
resection in the management of malignant gliomas: A systematic
review and meta-analysis. J Neurosurg. 112:1020–1032. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oppenlander ME, Wolf AB, Snyder LA, Bina
R, Wilson JR, Coons SW, Ashby LS, Brachman D, Nakaji P, Porter RW,
et al: An extent of resection threshold for recurrent glioblastoma
and its risk for neurological morbidity. J Neurosurg. 120:846–853.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kirson ED, Dbalý V, Tovarys F, Vymazal J,
Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S,
Gurvich Z, Schneidermann R, et al: Alternating electric fields
arrest cell proliferation in animal tumor models and human brain
tumors. Proc Natl Acad Sci USA. 104:10152–10157. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stupp R, Taillibert S, Kanner A, Read W,
Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K,
et al: Effect of tumor-treating fields plus maintenance
temozolomide vs. maintenance temozolomide alone on survival in
patients with glioblastoma: A Randomized Clinical Trial. JAMA.
318:2306–2316. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ram Z, Kim CY, Nicholas G and Toms S:
Compliance and treatment duration predict survival in a phase EF-14
trial of tumor treating fields with temozolomide in patients with
newly diagnosed glioblastoma. Neuro Oncol. 19 (Suppl 6):(6): pp.
vi6–vi7. 2017, https://doi.org/10.1093/neuonc/nox168.022
View Article : Google Scholar
|
|
9
|
Wen PY, Macdonald DR, Reardon DA,
Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert
MR, Lassman AB, et al: Updated response assessment criteria for
high-grade gliomas: Response assessment in neuro-oncology working
group. J Clin Oncol. 28:1963–1972. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Taphoorn MJB, Dirven L, Kanner AA,
Lavy-Shahaf G, Weinberg U, Taillibert S, Toms SA, Honnorat J, Chen
TC, Sroubek J, et al: Influence of treatment with tumor-treating
fields on health-related quality of life of patients with newly
diagnosed glioblastoma: A secondary analysis of a randomized
clinical trial. JAMA Oncol. 4:495–504. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stupp R, Wong ET, Kanner AA, Steinberg D,
Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F,
Dbalý V, et al: NovoTTF-100A versus physician's choice chemotherapy
in recurrent glioblastoma: A randomised phase III trial of a novel
treatment modality. Eur J Cancer. 48:2192–2202. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Onken J, Staub-Bartelt F, Vajkoczy P and
Misch M: Acceptance and compliance of TTFields treatment among high
grade glioma patients. J Neurooncol. 139:177–184. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hemminki K, Liu X, Försti A, Ji J,
Sundquist J and Sundquist K: Subsequent brain tumors in patients
with autoimmune disease. Neuro Oncol. 15:1142–1150. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ji J, Shu X, Sundquist K, Sundquist J and
Hemminki K: Cancer risk in hospitalised psoriasis patients: A
follow-up study in Sweden. Br J Cancer. 100:1499–1502. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Y, Li S, Zhang Z, Chen X, You G, Yang
P, Yan W, Bao ZS, Yao K, Wang L, et al: Surgical extent impacts the
value of the established prognosticators in glioblastoma patients:
A prospective translational study in Asia. Head Neck Oncol.
4:802012.
|
|
17
|
Beiko J, Suki D, Hess KR, Fox BD, Cheung
V, Cabral M, Shonka N, Gilbert MR, Sawaya R, Prabhu SS, et al: IDH1
mutant malignant astrocytomas are more amenable to surgical
resection and have a survival benefit associated with maximal
surgical resection. Neuro Oncol. 16:81–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bloch O, Han SJ, Cha S, Sun MZ, Aghi MK,
McDermott MW, Berger MS and Parsa AT: Impact of extent of resection
for recurrent glioblastoma on overall survival clinical article. J
Neurosurg. 117:1032–1038. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vymazal J and Wong ET: Response patterns
of recurrent glioblastomas treated with tumor-treating fields.
Semin Oncol. 41 (Suppl 6):S14–S24. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Combs SE, Rieken S, Wick W, Abdollahi A,
von Deimling A, Debus J and Hartmann C: Prognostic significance of
IDH-1 and MGMT in patients with glioblastoma: One step forward, and
one step back? Radiat Oncol. 6:1152011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Millward CP, Brodbelt AR, Haylock B,
Zakaria R, Baborie A, Crooks D, Husband D, Shenoy A, Wong H and
Jenkinson MD: The impact of MGMT methylation and IDH-1 mutation on
long-term outcome for glioblastoma treated with chemoradiotherapy.
Acta Neurochir (Wien). 158:1943–1953. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang P, Zhang W, Wang Y, Peng X, Chen B,
Qiu X, Li G, Li S, Wu C, Yao K, et al: IDH mutation and MGMT
promoter methylation in glioblastoma: Results of a prospective
registry. Oncotarget. 6:40896–40906. 2015. View Article : Google Scholar : PubMed/NCBI
|
